Question

Based on our understanding of genomic maintenance and genomic instability in cancer, how does the field of epigenetics complicate strategies for developing genome-based therapeutics?

Answer 1

Based on current information or studies on genetherapy and epigenetics it is definetly a complicated thing for genome based studies because genomics is said to be the tip of the iceberg and the deeper part is epigenetis. At present both the therapies are at the developing stages and has equal draw backs.

Epigenetics is trending and will be a world of change once it came into reality or practice, but some doubts like "new allele may not necessarily replace the original allele" has been expressed on the therapy. some believe that genes are responsible for longevity, epigenetics increase the life span and says that genomic modulations can make people ageless or look young. There are many such studies going on. I think epigenetics takes time to come into practice based on our current technology availability and we need more studies to understand the long term side effects of epigenetics. Even gene therapy has side effects which is caused by any pharmaceutical product. These may be improved with technology.

Complications to develop genome based therapy because of epigenetics are confined to the concept and understanding the concept makes it more complicated. Genetherapy is what initially everyone waited for but epigenetics is the future of medical practice.